The catch: authorized and regulatory certainty is minimal. Retatrutide was never ever to the FDA drug scarcity listing (as it was under no circumstances permitted), so compounders featuring it work underneath additional tenuous authorized framing than those who handled semaglutide or tirzepatide throughout the 2023–2024 shortages. Pricing might c